CROSS COUNTRY HEALTHCARE INC (CCRN) Stock Fundamental Analysis
NASDAQ:CCRN - Nasdaq - US2274831047 - Common Stock - Currency: USD
Overall CCRN gets a fundamental rating of 5 out of 10. We evaluated CCRN against 102 industry peers in the Health Care Providers & Services industry. CCRN has a great financial health rating, but its profitability evaluates not so good. CCRN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CCRN was profitable.
CCRN had a positive operating cash flow in the past year.
In multiple years CCRN reported negative net income over the last 5 years.
CCRN had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of CCRN (-2.47%) is comparable to the rest of the industry.
CCRN has a Return On Equity of -3.47%. This is comparable to the rest of the industry: CCRN outperforms 48.04% of its industry peers.
The Return On Invested Capital of CCRN (0.19%) is worse than 61.76% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CCRN is significantly above the industry average of 9.13%.
The 3 year average ROIC (15.05%) for CCRN is well above the current ROIC(0.19%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.47% | ||
| ROE | -3.47% | ||
| ROIC | 0.19% |
ROA(3y)9.37%
ROA(5y)8.5%
ROE(3y)17.7%
ROE(5y)17.81%
ROIC(3y)15.05%
ROIC(5y)13.58%
1.3 Margins
Looking at the Operating Margin, with a value of 0.09%, CCRN is doing worse than 62.75% of the companies in the same industry.
In the last couple of years the Operating Margin of CCRN has declined.
CCRN's Gross Margin of 20.41% is in line compared to the rest of the industry. CCRN outperforms 40.20% of its industry peers.
In the last couple of years the Gross Margin of CCRN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.09% | ||
| PM (TTM) | N/A | ||
| GM | 20.41% |
OM growth 3Y-77.97%
OM growth 5Y-33.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.01%
GM growth 5Y-3.83%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CCRN is creating some value.
CCRN has less shares outstanding than it did 1 year ago.
The number of shares outstanding for CCRN has been reduced compared to 5 years ago.
There is no outstanding debt for CCRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 4.80 indicates that CCRN is not in any danger for bankruptcy at the moment.
The Altman-Z score of CCRN (4.80) is better than 82.35% of its industry peers.
There is no outstanding debt for CCRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.8 |
ROIC/WACC0.02
WACC8.93%
2.3 Liquidity
A Current Ratio of 2.78 indicates that CCRN has no problem at all paying its short term obligations.
CCRN's Current ratio of 2.78 is amongst the best of the industry. CCRN outperforms 85.29% of its industry peers.
CCRN has a Quick Ratio of 2.78. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
CCRN has a better Quick ratio (2.78) than 85.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.78 | ||
| Quick Ratio | 2.78 |
3. Growth
3.1 Past
CCRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -79.64%.
The Earnings Per Share has been growing by 24.57% on average over the past years. This is a very strong growth
Looking at the last year, CCRN shows a very negative growth in Revenue. The Revenue has decreased by -33.46% in the last year.
CCRN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.33% yearly.
EPS 1Y (TTM)-79.64%
EPS 3Y-47.22%
EPS 5Y24.57%
EPS Q2Q%-86.21%
Revenue 1Y (TTM)-33.46%
Revenue growth 3Y-7.11%
Revenue growth 5Y10.33%
Sales Q2Q%-25.14%
3.2 Future
The Earnings Per Share is expected to grow by 11.41% on average over the next years. This is quite good.
CCRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.51% yearly.
EPS Next Y-14.19%
EPS Next 2Y10.43%
EPS Next 3Y11.41%
EPS Next 5YN/A
Revenue Next Year-7.39%
Revenue Next 2Y-1.62%
Revenue Next 3Y0.51%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 30.02 indicates a quite expensive valuation of CCRN.
CCRN's Price/Earnings ratio is in line with the industry average.
The average S&P500 Price/Earnings ratio is at 28.87. CCRN is around the same levels.
The Price/Forward Earnings ratio is 34.99, which means the current valuation is very expensive for CCRN.
CCRN's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of CCRN to the average of the S&P500 Index (21.38), we can say CCRN is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.02 | ||
| Fwd PE | 34.99 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CCRN is on the same level as its industry peers.
CCRN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CCRN is cheaper than 97.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.98 | ||
| EV/EBITDA | 18.58 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)1.22
EPS Next 2Y10.43%
EPS Next 3Y11.41%
5. Dividend
5.1 Amount
CCRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
13.51
-0.24 (-1.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners99.1%
Inst Owner Change0.06%
Ins Owners5.71%
Ins Owner Change0.18%
Market Cap442.99M
Analysts52.31
Price Target18.98 (40.49%)
Short Float %10.42%
Short Ratio7.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-21.94%
Min EPS beat(2)-66.11%
Max EPS beat(2)22.23%
EPS beat(4)2
Avg EPS beat(4)-15.28%
Min EPS beat(4)-66.11%
Max EPS beat(4)22.23%
EPS beat(8)5
Avg EPS beat(8)-5.24%
EPS beat(12)9
Avg EPS beat(12)1.38%
EPS beat(16)13
Avg EPS beat(16)11.46%
Revenue beat(2)0
Avg Revenue beat(2)-0.57%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)-0.41%
Revenue beat(4)0
Avg Revenue beat(4)-0.57%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)-0.41%
Revenue beat(8)2
Avg Revenue beat(8)-0.24%
Revenue beat(12)5
Avg Revenue beat(12)0.51%
Revenue beat(16)9
Avg Revenue beat(16)2.74%
PT rev (1m)6.6%
PT rev (3m)6.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-48.42%
EPS NY rev (1m)-5.69%
EPS NY rev (3m)-33.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.15%
Revenue NY rev (1m)-0.94%
Revenue NY rev (3m)-0.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.02 | ||
| Fwd PE | 34.99 | ||
| P/S | 0.33 | ||
| P/FCF | 3.98 | ||
| P/OCF | 3.69 | ||
| P/B | 1.06 | ||
| P/tB | 1.83 | ||
| EV/EBITDA | 18.58 |
EPS(TTM)0.45
EY3.33%
EPS(NY)0.39
Fwd EY2.86%
FCF(TTM)3.4
FCFY25.15%
OCF(TTM)3.66
OCFY27.11%
SpS40.99
BVpS12.78
TBVpS7.37
PEG (NY)N/A
PEG (5Y)1.22
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.47% | ||
| ROE | -3.47% | ||
| ROCE | 0.27% | ||
| ROIC | 0.19% | ||
| ROICexc | 0.23% | ||
| ROICexgc | 0.42% | ||
| OM | 0.09% | ||
| PM (TTM) | N/A | ||
| GM | 20.41% | ||
| FCFM | 8.29% |
ROA(3y)9.37%
ROA(5y)8.5%
ROE(3y)17.7%
ROE(5y)17.81%
ROIC(3y)15.05%
ROIC(5y)13.58%
ROICexc(3y)15.28%
ROICexc(5y)13.73%
ROICexgc(3y)22.9%
ROICexgc(5y)20.79%
ROCE(3y)21.31%
ROCE(5y)19.23%
ROICexcg growth 3Y-75.41%
ROICexcg growth 5Y-32.32%
ROICexc growth 3Y-77.25%
ROICexc growth 5Y-30.83%
OM growth 3Y-77.97%
OM growth 5Y-33.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.01%
GM growth 5Y-3.83%
F-Score4
Asset Turnover2.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 47.88% | ||
| Cap/Sales | 0.65% | ||
| Interest Coverage | 0.91 | ||
| Cash Conversion | 617.69% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.78 | ||
| Quick Ratio | 2.78 | ||
| Altman-Z | 4.8 |
F-Score4
WACC8.93%
ROIC/WACC0.02
Cap/Depr(3y)64.63%
Cap/Depr(5y)60.57%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-79.64%
EPS 3Y-47.22%
EPS 5Y24.57%
EPS Q2Q%-86.21%
EPS Next Y-14.19%
EPS Next 2Y10.43%
EPS Next 3Y11.41%
EPS Next 5YN/A
Revenue 1Y (TTM)-33.46%
Revenue growth 3Y-7.11%
Revenue growth 5Y10.33%
Sales Q2Q%-25.14%
Revenue Next Year-7.39%
Revenue Next 2Y-1.62%
Revenue Next 3Y0.51%
Revenue Next 5YN/A
EBIT growth 1Y-98.94%
EBIT growth 3Y-79.54%
EBIT growth 5Y-27.01%
EBIT Next Year791.51%
EBIT Next 3Y125.79%
EBIT Next 5YN/A
FCF growth 1Y-52.5%
FCF growth 3YN/A
FCF growth 5Y112.02%
OCF growth 1Y-51.66%
OCF growth 3YN/A
OCF growth 5Y85.29%